SCHEMBL85757

SCHEMBL85757

C#CCOC(C(=O)OCCO)c1ccc(Cl)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.35
SLC22A12 Q96S37 1/20 0.35
BRD4 O60885 1/20 0.34
NPC1 O15118 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
P2RX7 Q99572 1/20 0.33
PPARA Q07869 1/20 0.33
GPX4 P36969 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
CHRNB2 P17787 1/20 0.32
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32
CHRNA4 P43681 1/20 0.32
GABBR2 O75899 3/20 0.31
GABBR1 Q9UBS5 3/20 0.31
LMNA P02545 2/20 0.31
CYP2C9 P11712 2/20 0.31
FNTA P49354 1/20 0.31
FNTB P49356 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL76511 0.93 PPARG (0.37) PPARGSLC22A12BRD4NPC1MAOA
SCHEMBL77404 0.88 NPC1 (0.40) PPARGBRD4NPC1MAOAMAOB
SCHEMBL76267 0.83 L3MBTL1 (0.44) BRD4L3MBTL1MEN1KMT2A
SCHEMBL5917972 0.81 PPARG (0.36) PPARGBRD4NPC1MAOAMAOB
SCHEMBL75610 0.81 PPARG (0.46) PPARGMAOAMAOBPPARAGPX4
Hydrochloric Acid SCHEMBL5918049 0.80 PPARG (0.44) PPARGMAOAMAOBPPARAGPX4
SCHEMBL76084 0.70 LMNA (0.38) GPX4L3MBTL1LMNACYP2C9CYP2C19
SCHEMBL77607 0.69 TSHR (0.39) NPC1MAOAMAOBL3MBTL1LMNA
SCHEMBL5917965 0.68 IDO1 (0.32) GPX4GABBR2GABBR1LMNACYP2C9
SCHEMBL14558224 0.67 ADRB2 (0.41) LMNAMEN1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1919857-B1 PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF SYNGENTA PARTICIPATIONS AG (CH) 2016-03-09 EP disclosed
US-8129560-B2 Process for the synthesis of mandipropamid and derivatives thereof SYNGENTA CROP PROTECTION, INC. (US) 2012-03-06 US disclosed
US-8129560-B2 Process for the synthesis of mandipropamid and derivatives thereof SYNGENTA CROP PROTECTION, INC. (US) 2012-03-06 US disclosed
US-20090118532-A1 Process for the Synthesis of Mandipropamid and Derivatives Thereof SYNGENTA CROP PROTECTION, INC. (US) 2009-05-07 US disclosed
US-20090118532-A1 Process for the Synthesis of Mandipropamid and Derivatives Thereof SYNGENTA CROP PROTECTION, INC. (US) 2009-05-07 US disclosed
WO-2007020381-A2 PROCESS FOR THE SYNTHESIS OF MANDIPROPAMID AND DERIVATIVES THEREOF SYNGENTA PARTICIPATIONS AG (CH) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118532-A1 Process for the Synthesis of Mandipropamid and Derivatives Thereof OPRM1, OPRD1, ADRA1D PPARG 4173/4885SLC22A12 4212/4885BRD4 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.